Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond


Many stocks have been enjoying major gains as the bull market has persisted, driving up shares prices of companies across various indexes. If you're investing for the long term, what's more important is how a stock can perform over the long run versus a period of weeks or months.

While past performance isn't a guarantee of future returns, investing your cash into great companies well-positioned for long-term growth is always a good idea. If you have cash on hand this summer and want to put it into quality companies that can soar in the coming months and years, here are two worthy contenders to consider for your portfolio.

Vertex Pharmaceuticals (NASDAQ: VRTX) is known for its leadership in the field of cystic fibrosis therapeutics but is working to expand beyond this area and further cement its place in the rare-disease drug market. The company's flagship cystic fibrosis therapy Trikafta is approved to treat more than 90% of the U.S. patient population alone. Expanded approvals for Trikafta and Vertex's other cystic fibrosis drugs have helped the company to expand the cycle of use for patients, deepening its foothold in this broad total-addressable market.

Continue reading


Source Fool.com

Vertex Pharmaceuticals Inc. Aktie

430,00 €
-0,36 %
Die Vertex Pharmaceuticals Inc. Aktie notiert heute etwas tiefer, mit einem Rückgang von -0,36 %.
Deutliches Buy-Überwiegen bei Vertex Pharmaceuticals Inc. im Vergleich zu Sell-Einschätzungen.
Dadurch ergibt sich bei einem Kursziel von 440 € ein leicht positives Potenzial von 2.33% im Vergleich zum aktuellen Kurs von 430.0 € bei Vertex Pharmaceuticals Inc..
Like: 0
Teilen

Kommentare